Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, has embarked on the expansion of a vaccine manufacturing unit at its Biosciences Center Boxmeer campus in the Netherlands.
The $18 million investment will result in a doubling of the capacity of its Tissue Culture Department, one of the departments where antigens for viral and parasitological vaccines are manufactured for international markets.
The new facility, which is scheduled to be fully operational by early 2013, has been designed to operate with optimal efficiency as well as to meet current and future requirements with respect to Good Manufacturing Practice (GMP) and Safety, Health and Environment (SHE).
It will also allow for the anticipated globally growing demand for veterinary vaccines. In addition, the increase of the manufacturing capacity that will be realised anticipates for large-scale emergency production of veterinary vaccines when extensive amounts are needed within a short time period such as during outbreaks of emerging diseases.
Source: Merck Animal Health